机构：[1]Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou 510632, China.[2]School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.[3]Laboratory for the Analysis of Medicines, Department of Pharmaceutical Sciences, CIRM, University of Liege, B-4000 Liege, Belgium.[4]Occupational Health Laboratory, Anhui No. 2 Provincial People's Hospital/Anhui No. 2 Provincial People's Hospital Clinical College, Anhui Medical University, Hefei 230041, China.
The accurate and rapid detection of specific antibodies in blood is very important for efficient diagnosis and precise treatment. Conventional methods often suffer from time-consuming operations and/or a narrow detection range. In this work, for the rapid determination of bevacizumab in plasma, a series of chimeric hairpin DNA aptamer-based probes were designed by the modification, labeling and theoretical computation of an original aptamer. Then, the dissociation constant of the modified hairpin DNA to bevacizumab was measured and screened using microscale thermophoresis. The best chimeric hairpin DNA aptamer-based probe was then selected, and a one-step platform for the rapid determination of bevacizumab was constructed. This strategy has the advantages of being simple, fast and label-free. Because of the design and screening of the hairpin DNA, as well as the optimization of the concentration and electrochemical parameters, a low detection limit of 0.37 pM (0.054 ng mL-1) with a wide linear range (1 pM-1 μM) was obtained. Finally, the rationally constructed biosensor was successfully applied to the determination of bevacizumab in spiked samples, and it showed good accuracy and precision. This method is expected to truly realize accurate and rapid detection of bevacizumab and provides a new idea for the precise treatment of diseases.
基金：
This work was supported by the National Natural Science
Foundation of China (Grant No. 82273893, 82173773,
82304444), the Natural Science Foundation of Guangdong
Province, China (Grant No. 2022A1515011576,
2021A1515220099, 2021A0505030039, 2022A1515110641), and
the Anhui Medical University Research Foundation, China
(Grant No. 2022xkj123).
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]Institute of Traditional Chinese Medicine & Natural Products, College of Pharmacy/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou 510632, China.[2]School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Huang Shengfeng,Zhang Mengyun,Chen Feng,et al.A chimeric hairpin DNA aptamer-based biosensor for monitoring the therapeutic drug bevacizumab[J].The Analyst.2023,doi:10.1039/d3an01324c.
APA：
Huang Shengfeng,Zhang Mengyun,Chen Feng,Wu Huihui,Li Minyi...&Jiang Zhengjin.(2023).A chimeric hairpin DNA aptamer-based biosensor for monitoring the therapeutic drug bevacizumab.The Analyst,,
MLA：
Huang Shengfeng,et al."A chimeric hairpin DNA aptamer-based biosensor for monitoring the therapeutic drug bevacizumab".The Analyst .(2023)
